Every S-3 that Tenon Medical, Inc. (TNON) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow TNON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNON filings page.
Tenon Medical, Inc. (TNON) is registering up to 1,836,046 shares of common stock for resale by existing holders, primarily from prior private placements, equity compensation and the SiVantage asset acquisition. This is a resale registration; Tenon is not selling shares directly in this offering.
The registered shares include up to 597,610 Pre-Funded Warrant Shares, 1,058,517 August 2026 Series A Warrant Shares, 63,380 November 2025 Shares, related 63,380 November 2025 Warrant Shares, and smaller grants to executives, an employee and SiVantage. Assuming full exercise of the covered warrants and issuance of all SV Milestone Shares, Tenon expects 2,768,975 shares outstanding.
The company will receive no proceeds from stockholder resales, but may receive cash only upon exercise of the November 2025 and August 2026 warrants, which could total up to $7.9 million, intended for debt repayment, working capital and general corporate purposes. All share and per‑share data reflect a 1‑for‑35 reverse stock split effective August 10, 2026. Tenon’s auditors have issued an opinion on its 2024–2025 financial statements that includes substantial doubt about its ability to continue as a going concern.
Tenon Medical, Inc. is establishing a shelf registration that permits issuance, from time to time, of up to $100,000,000 of common stock, preferred stock, warrants, debt securities, rights, or units. Specific terms and pricing for each issuance will be set in separate prospectus supplements.
Within this shelf, Tenon has entered into an at-the-market (ATM) sales agreement with A.G.P./Alliance Global Partners to sell up to $4,397,821 of common stock on Nasdaq or other permitted markets. These primary offerings are limited by General Instruction I.B.6 to no more than one‑third of Tenon’s $13,193,463 public float in any 12‑month period while the float remains below $75 million.
Net proceeds are intended for expanding the commercial footprint of Tenon’s sacroiliac joint fusion portfolio (including clinician training and sales force expansion), clinical research to support reimbursement, research and development and new launches, added inventory and instrumentation, marketing, working capital, and other general corporate purposes. Tenon highlights its status as an emerging growth company and smaller reporting company and its auditor has included a going concern explanatory paragraph regarding the company’s ability to continue operations.
Tenon Medical, Inc. filed a Form S-3 shelf registration that permits the company to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, warrants, debt securities, rights, or units. The filing also includes an at-the-market program to sell up to $4,397,821 of common stock through A.G.P./Alliance Global Partners. Pursuant to General Instruction I.B.6, primary offerings are limited to one-third of Tenon’s public float. As of August 10, 2026, public float was $13,193,463, based on 606,596 non-affiliate shares. Auditors’ reports on 2025 and 2024 financial statements include an explanatory paragraph about substantial doubt regarding Tenon’s ability to continue as a going concern.
Tenon Medical, Inc. registers the resale of 6,296,246 shares of Common Stock by selling stockholders, including shares issued in a private placement, warrants exercisable for shares, employee and acquisition-related shares.
The prospectus states these are resale shares only; the Company will not receive proceeds from resale transactions but will receive proceeds from any cash exercise of warrants, which it intends to use for working capital.